Edition:
United Kingdom

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

97.92EUR
23 Feb 2018
Change (% chg)

€-0.52 (-0.53%)
Prev Close
€98.44
Open
€98.71
Day's High
€98.79
Day's Low
€97.58
Volume
2,015,889
Avg. Vol
2,442,642
52-wk High
€123.90
52-wk Low
€94.72

Latest Key Developments (Source: Significant Developments)

Monsanto Q1 Earnings Per Share $0.38
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Monsanto Co ::Q1 EARNINGS PER SHARE $0.38.Q1 EARNINGS PER SHARE VIEW $0.42 -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE $0.41 FROM CONTINUING OPERATIONS.QTRLY TOTAL NET SALES $2,658 MILLION VERSUS $2,650 MILLION LAST YEAR.-CONTINUES PROGRESS TOWARDS CLOSURE OF MERGER WITH BAYER IN EARLY PART OF 2018​.QTRLY TOTAL SEEDS AND GENOMICS SALES $1,770 MILLION VERSUS $1,848 MILLION LAST YEAR.INTACTA RR2 PRO(TM )SOYBEAN ADOPTION IN SOUTH AMERICA OFF TO A GOOD START IN Q1; ON PACE TO REACH 60 MILLION ACRES IN FY18.QUARTERLY RESULTS BENEFIT FROM HIGHER GLYPHOSATE PRICING.MONSANTO - EXPECTS GROWTH IN ITS PRETAX INCOME FOR FY 2018, BUT DID NOT PROVIDE SPECIFIC FINANCIAL GUIDANCE IN LIGHT OF PENDING COMBINATION WITH BAYER.MONSANTO - BRANDED ORDER MIX SUPPORTS EXPECTATIONS FOR 40 MILLION ACRES OF ROUNDUP READY 2 XTENDSOYBEANS IN FY 2018 IN U.S..MONSANTO SAYS CONTINUES PROGRESS TOWARDS CLOSURE OF MERGER WITH BAYER IN EARLY PART OF 2018.MONSANTO - ‍ EXPECTED GROWTH DRIVERS FOR 2018 ARE CONTINUED IMPROVEMENTS IN PRICING FOR GLYPHOSATE, ADOPTION OF NEW TECHNOLOGIES IN SEEDS AND GENOMICS.MONSANTO - CONTINUE TO EXPECT STRONG ADOPTION OF IMPROVED PRICING FOR GLYPHOSATE TO BE TEMPERED BY CHALLENGING GLOBAL CORN AND SOYBEAN PRICES.Q1 REVENUE VIEW $2.77 BILLION -- THOMSON REUTERS I/B/E/S.MONSANTO SEES ‍BENEFITS RELATED TO ASSET SALES,LICENSING CONTRIBUTIONS TO BE ABOUT 30 PERCENT BELOW ABOUT $350 MILLION PRE-TAX AVERAGE CONTRIBUTION FOR LAST 3 YRS.  Full Article

Bayer Announces Initiation Of Rolling Submission Of NDA In U.S. For Larotrectinib
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - BAYER AG ::INITIATION OF ROLLING SUBMISSION OF NDA IN U.S. FOR LAROTRECTINIB FOR TREATMENT OF TRK FUSION CANCERS​.‍COMPLETION OF NDA SUBMISSION EXPECTED IN EARLY 2018​.  Full Article

Bayer's Rivaroxaban Submitted To U.S. FDA For Approval
Monday, 11 Dec 2017 

Dec 11 (Reuters) - BAYER AG ::RIVAROXABAN SUBMITTED TO U.S. FDA FOR APPROVAL IN PATIENTS WITH CORONARY AND/OR PERIPHERAL ARTERY DISEASE.  Full Article

Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program
Friday, 24 Nov 2017 

Nov 24 (Reuters) - Nektar Therapeutics :Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs.Nektar Therapeutics - costs related to concluding co’s activities related to Bayer's phase 3 Amikacin Inhale clinical program under 2007 agreement.Nektar Therapeutics - based on discussion with Bayer, Nektar does not expect Bayer to move forward any further with the Amikacin Inhale program.  Full Article

Peptidream announces discovery collaboration agreement with Bayer
Monday, 20 Nov 2017 

Nov 19 (Reuters) - Peptidream Inc <4587.T>:Peptidream announces discovery collaboration agreement with bayer.‍Entered into a multi-target discovery collaboration with Germany-based Bayer AG​.Under terms , co would receive undisclosed upfront payment and research funding.Under terms, co is eligible to receive preclinical, clinical, commercialization milestone payments totaling up to $1.11 billion​.Also eligible to receive royalties on sales of any products that arise from collaboration​.  Full Article

PeptiDream announces discovery collaboration agreement with Bayer AG
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - PeptiDream Inc <4587.T>:Says it announced today that it has entered into a multi-target discovery collaboration with Germany-based Bayer AG.Under the terms of the agreement, it would receive an undisclosed upfront payment and research funding and is eligible to receive preclinical, clinical, and commercialization milestone payments potentially totaling up to $1.11 billion (124.5 billion yen) .In addition, it is eligible to receive royalties on sales of any products that arise from the collaboration .  Full Article

Bayer may terminate Loxo agreement if Larotrectinib is unapproved
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Loxo Oncology :Agreement with Bayer includes standstill provision preventing Bayer from acquiring 5 percent or more of co's voting securities​.Loxo says Bayer may terminate agreement if co gets CRL from U.S. Food and Drug agency with respect to Larotrectinib - SEC filing​.Bayer may terminate agreement if co does not get marketing approval for Larotrectinib by December 31, 2018​.  Full Article

Bayer, Loxo Oncology form partnership to develop, commercialise cancer drugs​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Bayer Ag :Says it and loxo oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer​.Says alliance to ‍target genetic drivers of cancer larotrectinib (loxo-101) and loxo-195 target tropomyosin receptor kinase (trk) fusion proteins​.Says ‍first filing for larotrectinib is planned in u.s. In late 2017 or early 2018, with eu filing expected in 2018.​.Says ‍loxo oncology will receive an upfront payment of usd 400 million and is eligible for usd 450 million in milestone payments​.Says ‍additional usd 200 million in milestone payments upon loxo-195 regulatory approvals and first commercial sale events in certain major markets.​.Says ‍will share development costs on a 50/50 basis.​.Says ‍bayer will lead ex-u.s. Regulatory activities, and worldwide commercial activities.​.Says ‍in u.s., where bayer and loxo oncology will co-promote products, parties will share commercial costs and profits on a 50/50 basis.​.Says ‍bayer will pay loxo oncology tiered double-digit percentage royalties on future net sales outside of u.s. And u.s. And ex-u.s. Sales milestones totaling usd 500 million.​.  Full Article

Loxo Oncology announces development and commercialization partnership with Bayer for cancer drugs
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Loxo Oncology Inc :Loxo Oncology announces global development and commercialization partnership with Bayer for larotrectinib and LOXO-195.Loxo Oncology Inc - ‍Loxo Oncology and Bayer to co-promote in U.S. with a 50/50 profit share; Bayer to commercialize RoW​.Loxo Oncology Inc - ‍under terms of agreement, Loxo Oncology will receive a $400 million upfront payment​.Loxo Oncology Inc - deal includes ‍up to $1.55 billion in upfront, regulatory, and commercial milestones​.Loxo Oncology - co eligible for $450 million in milestone payments upon larotrectinib approvals, first commercial sale events in some markets​.Loxo Oncology - co also eligible for additional $200 million in payments upon LOXO-195 approvals, first commercial sale events in some markets​.Loxo Oncology - ‍outside of U.S., ​Bayer will pay co royalties on sales, sales milestones totaling $475 million for larotrectinib & LOXO-195.  Full Article

CRISPR and Casebia collaborate with CureVac on mRNA for gene-editing programs
Monday, 13 Nov 2017 

Nov 13 (Reuters) - CRISPR Therapeutics AG :CRISPR Therapeutics and Casebia collaborate with CureVac on mRNA for gene-editing programs.‍Under terms, CureVac will develop novel Cas9 mRNA constructs with improved properties for gene editing applications​.‍In exchange, CureVac will receive an upfront payment and research funding ​.CRISPR Therapeutics-‍CureVac to also be eligible to receive development, commercial milestones, royalties on commercialized products from collaboration​.  Full Article

EU mergers and takeovers (Feb 23)

BRUSSELS, Feb 23 The following are mergers under review by the European Commission and a brief guide to the EU merger process: